---
title: "Pirtobrutinib sequencing in CLL: reasons for caution before first-line noncovalent BTK inhibition"
id: "pubmed-42678527"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42678527"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42678527/"
doi: "10.1007/s00277-026-07264-x"
published_at: "2026-09-01T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Pirtobrutinib sequencing in CLL: reasons for caution before first-line noncovalent BTK inhibition
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42678527
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42678527/)
- **DOI:** [10.1007/s00277-026-07264-x](https://doi.org/10.1007%2Fs00277-026-07264-x)
- **Published At:** 2026-09-01T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The phase III BRUIN CLL-313 and CLL-314 trials have positioned **pirtobrutinib**, a noncovalent **Bruton tyrosine kinase (BTK) inhibitor**, as a potential first-line option for chronic lymphocytic leukemia (CLL). - Regulatory action includes all-lines approval in the European Union for pirtobrutinib. - An asymmetry exists in available evidence: pirtobrutinib shows validated activity after failure of **covalent BTK inhibitors**, but the reverse sequence (using covalent BTK inhibitors after pirtobrutinib failure) lacks clinical data. - Specific kinase-domain mutations reported (for example, **A428D** and **L528W**) can arise after first-line pirtobrutinib and show in vitro cross-resistance to covalent BTK inhibitors, potentially compromising the current standard relapse management class. - There are no reported clinical outcomes for patients treated with covalent BTK inhibitors following pirtobrutinib failure; evidence is therefore lacking to guide reverse sequencing. - The authors argue for a cautious approach: maintain the clinically validated **covalent-first** sequence for patients likely to require multiple treatment lines until reverse-sequence data become available. - Practical suggestions include performing mutation testing at progression, creating registries to track post-pirtobrutinib outcomes, and explicitly addressing sequencing choices in guideline updates. - The correspondence emphasizes that recommendations are precautionary and grounded in the current evidence gap rather than new outcome data.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42678527/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42678527%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42678527/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42678527/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42678527/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42678527/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42678527/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42678527%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42678527%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42678527/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42678527/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42678527/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42678527/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42678527/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42678527/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42678527/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42678527/#conflict-of-interest) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42678527/#references) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42678527/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42678527/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42678527/#substances) Title & authors Abstract Conflict of interest statement References Publication types MeSH terms Substances Review Ann Hematol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Ann+Hematol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Ann+Hematol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) . 2026 Sep 1;105(9):404. doi: 10.1007/s00277-026-07264-x. # Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia [Boyi Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+B&cauthor_id=42678527)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42678527/#full-view-affiliation-1 "The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China."), [Shenxian Qian](https://pubmed.ncbi.nlm.nih.gov/?term=Qian+S&cauthor_id=42678527)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42678527/#full-view-affiliation-2 "Department of Hematology, Hangzhou First People's Hospital, Hangzhou, 310006, China. sysxqian@163.com.") Affiliations Expand ### Affiliations * 1 The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China. * 2 Department of Hematology, Hangzhou First People's Hospital, Hangzhou, 310006, China. sysxqian@163.com. * PMID: **42678527** * DOI: [ 10.1007/s00277-026-07264-x ](https://doi.org/10.1007/s00277-026-07264-x) Item in Clipboard Review # Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia Boyi Chen et al. Ann Hematol. 2026. Show details Display options Display options Format Abstract PubMed PMID Ann Hematol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Ann+Hematol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Ann+Hematol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) . 2026 Sep 1;105(9):404. doi: 10.1007/s00277-026-07264-x. ### Authors [Boyi Chen](https://pubmed.ncbi.nlm.nih.gov/?term=Chen+B&cauthor_id=42678527)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42678527/#short-view-affiliation-1 "The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China."), [Shenxian Qian](https://pubmed.ncbi.nlm.nih.gov/?term=Qian+S&cauthor_id=42678527)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42678527/#short-view-affiliation-2 "Department of Hematology, Hangzhou First People's Hospital, Hangzhou, 310006, China. sysxqian@163.com.") ### Affiliations * 1 The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China. * 2 Department of Hematology, Hangzhou First People's Hospital, Hangzhou, 310006, China. sysxqian@163.com. * PMID: **42678527** * DOI: [ 10.1007/s00277-026-07264-x ](https://doi.org/10.1007/s00277-026-07264-x) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID ## Abstract The phase III BRUIN CLL-313 and CLL-314 trials have established pirtobrutinib, a noncovalent Bruton tyrosine kinase (BTK) inhibitor, as a candidate for first-line therapy in chronic lymphocytic leukemia (CLL), and all-lines regulatory approval has now been granted in the European Union. We highlight an untested asymmetry: after failure of covalent BTK inhibitors, pirtobrutinib retains phase III-validated activity, whereas resistance to first-line pirtobrutinib can arise through kinase-domain mutations (e.g., A428D, L528W) that confer in vitro cross-resistance to covalent agents, the class that currently anchors relapse management. No clinical data exist on covalent BTK inhibitors after pirtobrutinib failure. We argue that, until reverse-sequence data emerge, a cautious approach that retains the clinically validated covalent-first sequence is reasonable for patients expected to need multiple lines of therapy, and we suggest mutation testing at progression, registry tracking of post-pirtobrutinib outcomes, and explicit discussion of sequencing in forthcoming guideline updates. **Keywords:** Bruton tyrosine kinase inhibitor; Chronic lymphocytic leukemia; Drug resistance; Pirtobrutinib; Treatment sequencing. © 2026. The Author(s). [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declarations. During the preparation of this work, AI-based tools were used for literature retrieval only; the authors reviewed and verified all content and take full responsibility for the integrity of the manuscript. Ethics approval: Ethics approval is not applicable to this correspondence. Competing interests: The authors declare no competing interests. ## References 1. 1. Jurczak W, Kwiatek M, Czyz J et al (2026) BRUIN CLL-313: randomized phase III trial of pirtobrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 44:466–475. - [DOI](https://doi.org/10.1200/jco-25-02380) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/41363773/) 2. 1. Woyach JA, Qiu L, Grosicki S et al (2026) Pirtobrutinib versus ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 44:476–485. - [DOI](https://doi.org/10.1200/jco-25-02477) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/41353787/) 3. 1. Davids MS (2026) The BRUIN 313 and 314 trials open the door for noncovalent Bruton tyrosine kinase inhibition as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 44:435–439. - [DOI](https://doi.org/10.1200/jco-25-02691) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/41363770/) 4. 1. European Medicines Agency (2026) Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22–25 June 2026. [https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal...](https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2026) ; European Commission approval of the all-lines indication disclosed in Eli Lilly and Company’s Q2 2026 results, 5 August 2026. Accessed 23 Aug 2026 5. 1. Mato AR, Woyach JA, Brown JR et al (2023) Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med 389:33–44. - [DOI](https://doi.org/10.1056/nejmoa2300696) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/37407001/) Show all 12 references ## Publication types * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Letter Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Letter%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Letter) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) ## MeSH terms * Adenine / analogs & derivatives Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adenine%2Fanalogs+and+derivatives%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Adenine) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Agammaglobulinaemia+Tyrosine+Kinase%2Fantagonists+and+inhibitors%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Agammaglobulinaemia+Tyrosine+Kinase) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Agammaglobulinaemia Tyrosine Kinase / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Agammaglobulinaemia+Tyrosine+Kinase%2Fgenetics%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Agammaglobulinaemia+Tyrosine+Kinase) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Clinical Trials, Phase III as Topic Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Clinical+Trials%2C+Phase+III+as+Topic%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Clinical+Trials%2C+Phase+III+as+Topic) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Drug Resistance, Neoplasm / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Drug+Resistance%2C+Neoplasm%2Fgenetics%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Resistance%2C+Neoplasm) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Humans Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Humans) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Leukemia%2C+Lymphocytic%2C+Chronic%2C+B-Cell%2Fdrug+therapy%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Leukemia%2C+Lymphocytic%2C+Chronic%2C+B-Cell) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Leukemia, Lymphocytic, Chronic, B-Cell* / enzymology Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Leukemia%2C+Lymphocytic%2C+Chronic%2C+B-Cell%2Fenzymology%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Leukemia%2C+Lymphocytic%2C+Chronic%2C+B-Cell) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Leukemia, Lymphocytic, Chronic, B-Cell* / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Leukemia%2C+Lymphocytic%2C+Chronic%2C+B-Cell%2Fgenetics%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Leukemia%2C+Lymphocytic%2C+Chronic%2C+B-Cell) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Mutation Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mutation%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Mutation) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Protein Kinase Inhibitors* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Protein+Kinase+Inhibitors%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Protein+Kinase+Inhibitors) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Protein-Tyrosine Kinases / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Protein-Tyrosine+Kinases%2Fgenetics%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Protein-Tyrosine+Kinases) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Pyrazoles Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Pyrazoles%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Pyrazoles) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Pyrimidines* / therapeutic use Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Pyrimidines%2Ftherapeutic+use%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Pyrimidines) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) ## Substances * Pyrimidines Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Pyrimidines%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Pyrimidines%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Protein Kinase Inhibitors Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Protein+Kinase+Inhibitors%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Protein+Kinase+Inhibitors%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Agammaglobulinaemia Tyrosine Kinase Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Agammaglobulinaemia+Tyrosine+Kinase%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Agammaglobulinaemia+Tyrosine+Kinase%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * BTK protein, human Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22BTK+protein%2C+human%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22BTK+protein%2C+human%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Protein-Tyrosine Kinases Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Protein-Tyrosine+Kinases%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Protein-Tyrosine+Kinases%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * Adenine Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adenine%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=%22Adenine%22) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42678527/) * pirtobrutinib Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22pirtobrutinib%22%5Bnm%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.go
## Related Clinical Research

- [Low-dose vemurafenib plus rituximab (Scripps regimen) for frontline and relapsed hairy cell leukem](https://medichelpline.com/clinical-feed/pubmed-42308249.md) (DOI: 10.1182/bloodadvances.2025019243)
- [Nemtabrutinib Plus Venetoclax vs Venetoclax Plus Rituximab in Relapsed/Refractory CLL/SLL](https://medichelpline.com/clinical-feed/clinicaltrials-nct05947851.md) (DOI: NCT05947851)
- [Tumour-selective CD20 expression enables rituximab repurposing for solid tumour immunotherapy](https://medichelpline.com/clinical-feed/pubmed-42671316.md) (DOI: 10.1002/ctm2.70804)
- [HCT–ASCT validated as superior consolidation versus non‑myeloablative chemoimmunotherapy for PCNSL](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-hct-asct-confirmed-as-standard-of-care-consolidation-therapy-for-pcnsl.md)
- [One-month physicochemical stability of idarubicin diluted in polyolefin (Freeflex) infusion bags](https://medichelpline.com/clinical-feed/plos-one-21-one-month-physicochemical-stability-study-of-idarubicin-prepared-in-polyolefin.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.